Quick answer: Glutathione taken by mouth is largely broken down in the gut before it reaches circulation intact, which is the pharmacokinetic reason other routes exist. Intravenous and subcutaneous administration bypass digestion entirely, liposomal formulations aim to shield the molecule during absorption, and precursor approaches such as N-acetylcysteine supply the raw material instead of the finished product. Route determines what actually reaches a cell, which makes it the first practical question rather than a technicality. Human research comparing the routes directly is still early.
Glutathione comes up most often in healthy aging conversations, where the interesting question is not whether the molecule matters but whether a given product actually delivers it. Route of administration decides that, because a molecule has to survive the trip to do anything at all. Glutathione makes the point unusually clear, since the gap between what is swallowed and what reaches the bloodstream is large and well documented.
Why the oral route loses so much
Glutathione swallowed as a supplement meets digestive enzymes and gut wall metabolism before reaching the portal circulation. Much of the intact tripeptide is dismantled into glutamate, cysteine and glycine along the way, and those amino acids are absorbed and can be reused, though the finished molecule largely is not. Human studies attempting to raise circulating glutathione by oral dosing have produced mixed results, with some showing little change in blood levels.
Digestive breakdown is not specific to glutathione. Short peptides generally fare poorly when swallowed, which is why so much of the peptide category is injected, as described in the plain explanation of what peptides are. Recognising that pattern makes the rest of the route discussion straightforward.
Intravenous glutathione
Intravenous administration places glutathione directly into the bloodstream and removes the absorption question entirely. Blood levels rise sharply and predictably, which is the clearest pharmacokinetic argument for the route. Rising plasma concentration does not by itself establish how much enters cells, and intracellular delivery is where the human data are thinnest.
Infusions carry the ordinary considerations of any intravenous procedure, including infection risk and vein irritation, and they require clinical administration by trained staff. Practical access is the other constraint, since each session means a clinic visit.
Subcutaneous administration
Subcutaneous injection deposits a compound into the tissue under the skin, from which it is absorbed into circulation more gradually than an infusion delivers it. Practicality is the main appeal, since the route does not require a vein or a clinic visit each time. Peptide therapies prescribed through telehealth commonly use this route for that reason.
Absorption, stability and tissue distribution differ molecule by molecule, so a route that suits one peptide does not automatically suit another. Any subcutaneous therapy is a prescription decision a clinician makes after an evaluation, and the product itself should come from a licensed US pharmacy with third-party testing behind it.
Liposomal and other oral workarounds
Liposomal formulations enclose glutathione in lipid vesicles that protect it from digestive breakdown and improve uptake, a well-founded principle in pharmaceutics. Laboratory work supports the mechanism, and the human trials of liposomal glutathione so far are small and short. Sublingual and buccal formats attempt something similar by absorbing the molecule through the mouth lining before it reaches the stomach.
Reading formulation claims well means separating what was shown in a laboratory from what was shown in people, a distinction set out in the guide to reading peptide evidence. Formulation science is genuinely advancing here, and the clinical picture is catching up behind it.
Precursor approaches such as NAC
Precursor strategies sidestep the delivery problem by supplying what cells need to build glutathione themselves. N-acetylcysteine is the most studied example, since cysteine is normally the limiting ingredient in synthesis. NAC has a long-standing role in hospital medicine for acetaminophen overdose, administered under clinical supervision, and that specific use rests on much stronger evidence than any wellness application.
Glycine has also been studied alongside cysteine as a combined precursor approach, mostly in small human studies in older adults, and the healthy aging angle is what makes that work interesting. Precursor approaches have the appeal of working with cellular machinery rather than pushing a finished molecule past the gut, a mechanism described further in the overview of what glutathione is and does.
Where the research stands
Delivery pharmacokinetics for glutathione are well described, and clinical outcomes by route are not yet. Much of the current understanding comes from laboratory and animal work, human trials remain early and mostly small, and few studies place two routes side by side in the same population with the same endpoints. Skin lightening is a widely marketed use of injectable glutathione that the evidence does not support, and Everhuman makes no such claim.
Glutathione is listed as coming soon on the Everhuman site and is not currently offered, so nothing here describes something a reader can start today. Everhuman's standards hold across the catalogue: American made, third-party tested, dispensed by licensed US pharmacies, and prescribed only after an evaluation by a licensed clinician through Arora Health. Delivery questions run through the wider category too, including in the comparison of NAD delivery methods.
Frequently Asked Questions
Why is oral glutathione poorly absorbed?
Oral glutathione is largely broken down by digestive enzymes and gut wall metabolism into its three component amino acids before reaching circulation. Those amino acids can be reused for synthesis, though the intact tripeptide mostly does not survive the trip. Limited survival of the intact molecule is the reason alternative routes are studied.
Is intravenous glutathione better than oral?
Intravenous administration reliably raises blood levels in a way oral dosing does not, which is a real pharmacokinetic difference. Higher blood levels are not the same as a demonstrated clinical outcome, and human trials of intravenous glutathione remain small and largely confined to specific patient groups. Infusions also require clinical administration.
Does liposomal glutathione work?
Liposomal encapsulation is a sound strategy for protecting fragile molecules during absorption, and laboratory work supports the principle. Human trials of liposomal glutathione are small and short so far, which puts the approach at the promising stage. Laboratory findings and clinical results are worth keeping separate here.
Is NAC a substitute for glutathione?
NAC supplies cysteine, the ingredient cells most often lack when building glutathione, so it functions as a precursor rather than a replacement. Hospital use of NAC for acetaminophen overdose is well established and clinically supervised. Wellness applications rest on a considerably thinner evidence base than that clinical use.
Can glutathione be taken as a pill?
Glutathione pills exist and are widely sold, though the intact molecule is largely degraded before absorption, which makes the pill format the weakest option on pharmacokinetic grounds. Precursor supplements take a different path toward the same goal. Any prescription route requires a clinician evaluation and a decision that treatment is appropriate.
Can I start glutathione with Everhuman now?
Glutathione is listed as coming soon on the Everhuman site and is not currently available, so this article is educational only. Everhuman does not provide medical advice, and clinical care is delivered by Arora Health. Readers interested in currently offered therapies can review the explainer on sermorelin instead.
The honest summary
Route of administration is the most consequential variable in the glutathione conversation, because swallowing the intact molecule mostly does not deliver it. Intravenous administration solves absorption and leaves intracellular delivery an open question, subcutaneous use is the practical outpatient route, liposomal formats are the promising oral workaround, and precursor approaches carry the deepest evidence within a narrow clinical context. Human trials comparing them head to head are the work still to be done.
Glutathione is not currently offered by Everhuman, and any prescription therapy is a clinical decision reached after an evaluation. Restoration is the aim here, not transformation.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European journal of nutrition. 2015. PMID 24791752.
Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study. Redox biology. 2015. PMID 26262996.
High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. European journal of clinical investigation. 1991. PMID 1907548.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.